The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
The approval introduces a needle-free alternative to injectable GLP-1 therapies
Elanco expects Befrena to launch in the US in the first half of 2026
The study met its primary endpoint with flying colors
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Subscribe To Our Newsletter & Stay Updated
